Parallel artificial-membrane permeability

Kansy, M., Senner, F., Gubemator, K. Physicochemical high throughput screening parallel artificial membrane permeability assay in the description of passive absorption processes. J. Med. Chem. 1998, 41, 1007-1010. [Pg.83]

Typical early in vitro permeability assessments measure the rate of flux of a compound from one side of a barrier to another [54, 55]. The barrier has historically been derived from a cell line, most commonly Caco-2 or Madin-Darby canine kidney (MDCK) cells. In the last several years, there has been substantial work and significant progress in the development of parallel artificial membrane permeability... [Pg.159]

BBB PAMPA Blood brain barrier parallel artificial membrane permeability assay... [Pg.176]

PARALLEL ARTIFICIAL-MEMBRANE PERMEABILITY ASSAY (PAMPA)... [Pg.128]

Zhu, C. Chen, T.-M. Hwang, K., A comparative study of parallel artificial membrane permeability assay for passive absorption screening, in CPS A2000 The Symposium on Chemical and Pharmaceutical Structure Analysis. Milestone Development Services. Princeton, NJ, Sept. 26-28, 2000. [Pg.281]

Sugano, K. Hamada, H. Machida, M. Ushio, H., High throughput prediction of oral absorption Improvement of the composition of the lipid solution used in parallel artificial membrane permeability assay, J. Biomolec. Screen. 6, 189-196 (2001). [Pg.281]

This book is written for the practicing pharmaceutical scientist involved in absorption-distribution-metabolism-excretion (ADME) measurements who needs to communicate with medicinal chemists persuasively, so that newly synthesized molecules will be more drug-like. ADME is all about a day in the life of a drug molecule (absorption, distribution, metabolism, and excretion). Specifically, this book attempts to describe the state of the art in measurement of ionization constants (p Ka), oil-water partition coefficients (log PI log D), solubility, and permeability (artificial phospholipid membrane barriers). Permeability is covered in considerable detail, based on a newly developed methodology known as parallel artificial membrane permeability assay (PAMPA). [Pg.299]

Kerns EH, Di L, Petusky S, Farris M, Ley R, Jupp P (2004) Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharm Sci 93 1440-1453. [Pg.209]

Table 18.3 Parallel artificial membrane permeability assay (PAMPA) permeability and human absorption for 19 drug compounds.

Galinis-Luciani, D., Nguyen, L. and Yazdanian, M. (2007) Is parallel artificial membrane permeability assay a useful tool for discovery Journal of Pharmaceutical Sciences, 96, 2886-2892. [Pg.139]

Avdeef, A., Bendels, S., Di, L., Fallen B., Kansy, M., Sugano, K. and Yamauchi, Y. (2007) Parallel artificial membrane permeability assay (PAMPA)-critical factors for better predictions of absorption. Journal of Pharmaceutical Sciences, 96, 2893-2909. [Pg.139]

A novel design of artificial membrane for improving the parallel artificial membrane permeability assay model. Pharmaceutical Research, 25, 1511-1520. [Pg.140]

A novel application of the parallel artificial membrane permeability assay (PAM-PA) system to measuring protein binding constants was demonstrated recently [41]. [Pg.205]

Abbreviations ADME, Adsorption distribution metabolism excretion CSF, Cerebrospinal fluid PAMPA, Parallel artificial membrane permeability assay. [Pg.325]

To predict in vivo permeabilities, the parallel artificial membrane permeability assay (PAMPA) was introduced in 1998. Since then, it has gathered considerable interest in the pharmaceutical industry [41-47]. This method uses a phospholipid-coated filter separating two aqueous compartments to mimic the passive transport of small molecules. It readily provides information about passive-transport perme-... [Pg.104]